Mediastinal Neoplasms

• EMA approval · 2026-08-06
  EMA Authorised: Breyanzi (lisocabtagene maraleucel) — Bristol-Myers Squibb Pharma EEIG

  The EMA has authorised Breyanzi (lisocabtagene maraleucel) for specified lymphomas, including large B-cell diffuse and follicular lymphoma, …

• CLINICAL_TRIALS research · 2026-03-05
  Clinical Trial Update: Phase II Trial of Lung Chemoemobolization [Phase 2]

  Phase II trial of lung chemoembolization is currently recruiting. The listed indications include non-small cell lung cancer, mediastinal and…

• EMA approval · 2025-12-18
  EMA Authorised: Breyanzi (lisocabtagene maraleucel) — Bristol-Myers Squibb Pharma EEIG

  The EMA authorised Breyanzi (lisocabtagene maraleucel) for additional lymphomas, including diffuse large B-cell lymphoma and follicular lymp…

• CLINICAL_TRIALS research · 2025-07-15
  Clinical Trial Update: Tubeless VATS for Mediastinal Neoplasm [NA]

  Clinical trial update showing the study is recruiting to evaluate tubeless, non-intubated VATS for mediastinal neoplasms.

• CLINICAL_TRIALS trial_result · 2022-08-19
  Clinical Trial Update: Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults [Phase 4]

  Phase 4 clinical trial update for newly diagnosed mature B-ALL, Burkitt's lymphoma, and other high-grade lymphomas in adults has completed.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2022-05-11
  Clinical Trial Update: Pain and Quality of Life After Mediastinal Tumor Resection by Subxiphoid and Intercostal VATS [Phase 3]

  Phase 3 clinical trial evaluating pain and quality of life after mediastinal tumor resection using subxiphoid and intercostal VATS, status c…

• CLINICAL_TRIALS trial_result · 2018-04-17
  Clinical Trial Update: Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors [Phase 2]

  Phase 2 trial of pembrolizumab in incurable platinum-refractory germ cell tumors was terminated; results posted in 2018.